Federal Courts Address “Patient” Eligibility Under 340B Drug Pricing Program
This Bulletin is brought to you by AHLA’s Hospitals and Health Systems Practice Group.
- August 31, 2022
- Jeff Davis , Bass Berry & Sims PLC
A recent decision by the Fourth Circuit could have significant implications for the ability of hospitals and other health care providers participating in the 340B drug pricing program (covered entities) to generate program savings. On July 1, 2022, the Fourth Circuit issued a decision in Genesis Healthcare, Inc. v. Becerra, finding that a covered entity’s challenge against the government on the definition of a 340B-eligible patient can continue.
You must be logged in to access this content.